ArticleEuropean journal of nuclear medicine and molecular imaging2009
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
Article in European journal of nuclear medicine and molecular imaging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Repeatability of quantitativeEuropean journal of nuclear medicine and molecular imaging · 2018Pooled it
- Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.Molecular imaging and biology · 2014Trial
- 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.European journal of nuclear medicine and molecular imaging · 2012Trial
- Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Article
- Role of 3'-Deoxy-3'-[JTO clinical and research reports · 2022Article
- Dynamic whole-body PET imaging: principles, potentials and applications.European journal of nuclear medicine and molecular imaging · 2019Review
- Repeatability ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2015Article
- Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.EJNMMI research · 2015Article
- Heterogeneity in stabilization phenomena in FLT PET images of canines.Physics in medicine and biology · 2014Article
- Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.British journal of cancer · 2014Article
- Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.European journal of nuclear medicine and molecular imaging · 2014Article
- FLT PET-CT in evaluation of treatment response.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India · 2014Review
- Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.European journal of nuclear medicine and molecular imaging · 2014Article
- 18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.EJNMMI research · 2014Article
- Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.BioMed research international · 2014Article
- Predicting tumour response.Cancer imaging : the official publication of the International Cancer Imaging Society · 2013Review
- Article
- Validity of simplified 3'-deoxy-3'-[18F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer.Molecular imaging and biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePositron emission tomography (PET) using (18)F-3'-deoxy-3'-fluorothymidine ([(18)F]FLT) allows noninvasive monitoring of tumour proliferation. For serial imaging in individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative [(18)F]FLT measurements.
methodsNine patients with non-small-cell lung cancer (NSCLC) and six with head-and-neck cancer (HNC) underwent [(18)F]FLT PET twice within 7 days prior to therapy. The maximum pixel value (SUV(max)) and a threshold defined volume (SUV(41%)) were defined for all delineated lesions. The plasma to tumour transfer constant (K(i)) was estimated using both Patlak graphical analysis and nonlinear regression (NLR). NLR was also used to estimate k(3), which, at least in theory, selectively reflects thymidine kinase 1 activity. The level of agreement between test and retest values was assessed using the intraclass correlation coefficient (ICC) and Bland-Altman analysis.
resultsAll primary tumours and >90% of clinically suspected locoregional metastases could be delineated. In total, 24 lesions were defined. NLR-derived K(i), Patlak-derived K(i), SUV(41%) and SUV(max) showed excellent reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and SDs of 16%, 12%, 7% and 11%, respectively. Reproducibility was poor for k(3) with an ICC of 0.43 and SD of 38%.
conclusionQuantitative [(18)F]FLT measurements are reproducible in both NSCLC and HNC patients. When monitoring response in individual patients, changes of more than 15% in SUV(41%), 20-25% in SUV(max) and Patlak-derived K(i), and 32% in NLR3k-derived K(i) are likely to represent treatment effects.
Indexed as
Identifiers
18931838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.